RNA-seq analysis of SMARCA4-deficient NCI-H838 xenograft tumors treated with PRT3789, docetaxel, nab-paclitaxel, or combination regimens
RNA-seq (gene expression) · human · 26 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Homo sapiens (human)
- Samples
- 26 samples
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE307427_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1321661 and SRA study SRP618258. Searching any of these in the dataset finder brings you back here.
The sample list for this study is not cached yet. Press Load samples and it will be fetched from NCBI.
+ 26 more — browse all 26 samples with per-sample file links →
- GSE307424 RNA-seq analysis of NCI-H1693 cells treated with the selective SMARCA2 degrader PRT3789 18 samples shares prt3789
- GSE307426 ATAC-seq analysis of NCI-H1693 cells treated with the selective SMARCA2 degrader PRT3789 5 samples shares prt3789
- GSE316195 A Phase 1 clinical trial and single-cell correlates of motixafortide, cemiplimab, gemcitabine and nab-paclitaxel for metastatic treatment-naïve metastatic pancreatic ductal adenocarcinoma. 22 samples shares nab-paclitaxel
- GSE288533 Neoadjuvant BMS-813160, nivolumab, gemcitabine and nab-paclitaxel for pancreatic cancer 14 samples shares nab-paclitaxel
- GSE307259 c-JUN Enhances CRISPR Knock-In anti-B7-H3 CAR T-cell Function for Treatment of Small Cell Lung Cancer and thoracic SMARCA4-deficient undifferentiated tumors 12 samples shares smarca4-deficient
- GSE262746 Nab-paclitaxel induces DNA damage and inhibits M2 polarization of macrophages to achieve radiosensitization of cholangiocarcinoma cells. 12 samples shares nab-paclitaxel
- GSE328872 Comparative transcriptomic profiling of TRI-LC21 and BEAS-2B cells to investigate SMARCA4-deficient undifferentiated tumor 6 samples shares smarca4-deficient
- GSE233746 Phase II Clinical Trial of Nab-Paclitaxel (NAB)Plus Cisplatin (PLA) Plus Gemcitabine (GEM) (NABPLAGEM) in Patients with Untreated Advanced Pancreatic Cancer. 2 samples shares nab-paclitaxel
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.